Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (115)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Boldog, F.
Right arrow Articles by Drabkin, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boldog, F.
Right arrow Articles by Drabkin, H. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 6, 193-203, Copyright © 1997 by Oxford University Press

ARTICLES

Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B

F Boldog, RM Gemmill, J West, M Robinson, L Robinson, E Li, J Roche, S Todd, B Waggoner, R Lundstrom, J Jacobson, MR Mullokandov, H Klinger and HA Drabkin
Division of Medical Oncology, University of Colorado Health Sciences Center, Denver 80262, USA.

Loss of heterozygosity (LOH) involving 3p occurs in many carcinomas but is complicated by the identification of four distinct homozygous deletion regions. One putative target, 3p14.2, contains the common fragile site, FRA3B, a hereditary renal carcinoma-associated 3;8 translocation and the candidate tumor suppressor gene, FHIT. Using a approximately 300 kb comsid/lambda contig, we identified homozygous deletions in cervix, breast, lung and colorectal carcinoma cell lines. The smallest deletion (CC19) was shown not to involve FHIT coding exons and no DNA sequence alterations were present in the transcript. We also detected discontinuous deletions as well as deletions in non-tumor DNAs, suggesting that FHIT is not a selective target. Further, we demonstrate that some reported FHIT aberrations represent normal splicing variation. DNA sequence analysis of 110 kb demonstrated that the region is high in A-T content, LINEs and MER repeats, whereas Alu elements are reduced. We note an intriguing similarity in repeat sequence composition between FRA3B and a 152 kb segment from the Fragile-X region. We also identified similarity between a FRA3B segment and a small polydispersed circular DNA. In contrast to the selective loss of a tumor suppressor gene, we propose an alternative hypothesis, that some putative targets including FRA3B may undergo loss as a consequence of genomic instability. This instability is not due to DNA mismatch repair deficiency, but may correlate in part with p53 inactivation.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. G. Durkin, R. L. Ragland, M. F. Arlt, J. G. Mulle, S. T. Warren, and T. W. Glover
Replication stress induces tumor-like microdeletions in FHIT/FRA3B
PNAS, January 8, 2008; 105(1): 246 - 251.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
T. W. Glover, M. F. Arlt, A. M. Casper, and S. G. Durkin
Mechanisms of common fragile site instability
Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R197 - R205.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
D. J. Mulvihill and Y.-H. Wang
Two Breakpoint Clusters at Fragile Site FRA3B Form Phased Nucleosomes
Genome Res., July 1, 2004; 14(7): 1350 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Kim, Y. M. Kwon, J. S. Kim, H. Lee, J.-H. Park, Y. M. Shim, J. Han, J. Park, and D.-H. Kim
Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung Cancer
J. Clin. Oncol., June 15, 2004; 22(12): 2363 - 2370.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Ciullo, M.-A. Debily, L. Rozier, M. Autiero, A. Billault, V. Mayau, S. El Marhomy, J. Guardiola, A. Bernheim, P. Coullin, et al.
Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I
Hum. Mol. Genet., November 1, 2002; 11(23): 2887 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Corbin, M. E. Neilly, R. Espinosa III, E. M. Davis, T. W. McKeithan, and M. M. Le Beau
Identification of Unstable Sequences within the Common Fragile Site at 3p14.2: Implications for the Mechanism of Deletions within Fragile Histidine Triad Gene/Common Fragile Site at 3p14.2 in Tumors
Cancer Res., June 1, 2002; 62(12): 3477 - 3484.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. I. Wistuba, R. Ashfaq, A. Maitra, H. Alvarez, E. Riquelme, and A. F. Gazdar
Fragile Histidine Triad Gene Abnormalities in the Pathogenesis of Gallbladder Carcinoma
Am. J. Pathol., June 1, 2002; 160(6): 2073 - 2079.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Maitra, I. I. Wistuba, C. Washington, A. K. Virmani, R. Ashfaq, S. Milchgrub, A. F. Gazdar, and J. D. Minna
High-Resolution Chromosome 3p Allelotyping of Breast Carcinomas and Precursor Lesions Demonstrates Frequent Loss of Heterozygosity and a Discontinuous Pattern of Allele Loss
Am. J. Pathol., July 1, 2001; 159(1): 119 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. D. Kholodnyuk, A. Szeles, Y. Yang, G. Klein, and S. Imreh
Inactivation of the Human Fragile Histidine Triad Gene at 3p14.2 in Monochromosomal Human/Mouse Microcell Hybrid-derived Severe Combined Immunodeficient Mouse Tumors
Cancer Res., December 1, 2000; 60(24): 7119 - 7125.
[Abstract] [Full Text]

Home page
 Hum Mol GenetHome page
K. Ried, M. Finnis, L. Hobson, M. Mangelsdorf, S. Dayan, J. K. Nancarrow, E. Woollatt, G. Kremmidiotis, A. Gardner, D. Venter, et al.
Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells
Hum. Mol. Genet., July 1, 2000; 9(11): 1651 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. I. Wistuba, C. Behrens, A. K. Virmani, G. Mele, S. Milchgrub, L. Girard, J. W. Fondon III, H. R. Garner, B. McKay, F. Latif, et al.
High Resolution Chromosome 3p Allelotyping of Human Lung Cancer and Preneoplastic/Preinvasive Bronchial Epithelium Reveals Multiple, Discontinuous Sites of 3p Allele Loss and Three Regions of Frequent Breakpoints
Cancer Res., April 1, 2000; 60(7): 1949 - 1960.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
M. Mangelsdorf, K. Ried, E. Woollatt, S. Dayan, H. Eyre, M. Finnis, L. Hobson, J. Nancarrow, D. Venter, E. Baker, et al.
Chromosomal Fragile Site FRA16D and DNA Instability in Cancer
Cancer Res., March 1, 2000; 60(6): 1683 - 1689.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
A. J. W. Paige, K. J. Taylor, A. Stewart, J. G. Sgouros, H. Gabra, G. C. Sellar, J. F. Smyth, D. J. Porteous, and J. E. V. Watson
A 700-kb Physical Map of a Region of 16q23.2 Homozygously Deleted in Multiple Cancers and Spanning the Common Fragile Site FRA16D
Cancer Res., March 1, 2000; 60(6): 1690 - 1697.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
R. Wu, D. C. Connolly, R. L. Dunn, and K. R. Cho
Restored Expression of Fragile Histidine Triad Protein and Tumorigenicity of Cervical Carcinoma Cells
J Natl Cancer Inst, February 16, 2000; 92(4): 338 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Gramantieri, P. Chieco, M. Di Tomaso, L. Masi, F. Piscaglia, S. Brillanti, S. Gaiani, M. Valgimigli, A. Mazziotti, and L. Bolondi
Aberrant Fragile Histidine Triad Gene Transcripts in Primary Hepatocellular Carcinoma and Liver Cirrhosis
Clin. Cancer Res., November 1, 1999; 5(11): 3468 - 3475.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. Julicher, G. Marquitan, N. Werner, W. Bardenheuer, L. Vieten, F. Brocker, H. Topal, S. Seeber, B. Opalka, and J. Schutte
Novel Tumor Suppressor Locus in Human Chromosome Region 3p14.2
J Natl Cancer Inst, September 15, 1999; 91(18): 1563 - 1568.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Hallas, M. Albitar, J. Letofsky, M. J. Keating, K. Huebner, and C. M. Croce
Loss of FHIT Expression in Acute Lymphoblastic Leukemia
Clin. Cancer Res., September 1, 1999; 5(9): 2409 - 2414.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Kohno and J. Yokota1
How many tumor suppressor genes are involved in human lung carcinogenesis?
Carcinogenesis, August 1, 1999; 20(8): 1403 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, R. Calvo, J. J. Sanchez, J. Maurel, M. Guillot, M. Monzo, L. Nunez, and A. Barnadas
Genetic Susceptibility Associated with Rare HRAS1 Variable Number of Tandem Repeats Alleles in Spanish Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., July 1, 1999; 5(7): 1849 - 1854.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Mimori, T. Druck, H. Inoue, H. Alder, L. Berk, M. Mori, K. Huebner, and C. M. Croce
Cancer-specific chromosome alterations in the constitutive fragile region FRA3B
PNAS, June 22, 1999; 96(13): 7456 - 7461.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Croce, G. Sozzi, and K. Huebner
Role of FHIT in Human Cancer
J. Clin. Oncol., May 1, 1999; 17(5): 1618 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Turker, B. M. Gage, J. A. Rose, D. Elroy, O. N. Ponomareva, P. J. Stambrook, and J. A. Tischfield
A Novel Signature Mutation for Oxidative Damage Resembles a Mutational Pattern Found Commonly in Human Cancers
Cancer Res., April 1, 1999; 59(8): 1837 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. M. Gemmill, J. D. West, F. Boldog, N. Tanaka, L. J. Robinson, D. I. Smith, F. Li, and H. A. Drabkin
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8
PNAS, August 4, 1998; 95(16): 9572 - 9577.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Mishmar, A. Rahat, S. W. Scherer, G. Nyakatura, B. Hinzmann, Y. Kohwi, Y. Mandel-Gutfroind, J. R. Lee, B. Drescher, D. E. Sas, et al.
Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site
PNAS, July 7, 1998; 95(14): 8141 - 8146.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. C. Pace, P. N. Garrison, A. K. Robinson, L. D. Barnes, A. Draganescu, A. Rosler, G. M. Blackburn, Z. Siprashvili, C. M. Croce, K. Huebner, et al.
Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit
PNAS, May 12, 1998; 95(10): 5484 - 5489.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. Palin, R Critcher, D. Fitzgerald, J. Anderson, and C. Farr
Direct cloning and analysis of DNA sequences from a region of the Chinese hamster genome associated with aphidicolin-sensitive fragility
J. Cell Sci., January 6, 1998; 111(12): 1623 - 1634.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Inoue, H. Ishii, H. Alder, E. Snyder, T. Druck, K. Huebner, and C. M. Croce
Sequence of the FRA3B common fragile region: Implications for the mechanism of FHIT deletion
PNAS, December 23, 1997; 94(26): 14584 - 14589.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Z. Siprashvili, G. Sozzi, L. D. Barnes, P. McCue, A. K. Robinson, V. Eryomin, L. Sard, E. Tagliabue, A. Greco, L. Fusetti, et al.
Replacement of Fhit in cancer cells suppresses tumorigenicity
PNAS, December 9, 1997; 94(25): 13771 - 13776.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.